StockData
Denali Therapeutics Inc. logo

Denali Therapeutics Inc. (DNLI) stock

DNLINasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 6/30
$18.00−0.08 (-0.44%)

Close on Nov 17, 2026Market cap $2.88BP/E –Yield –

Denali Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Denali Therapeutics's revenue for the twelve months ending Dec 31, 2024 was $0, down 100.0% year over year. For fiscal 2025 it was $0. The highest annual figure on record is $335.66M in fiscal 2020.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$0–
FY2024Dec 31, 2024$0-100.0%
FY2023Dec 31, 2023$330.53M+204.7%
FY2022Dec 31, 2022$108.46M+122.9%
FY2021Dec 31, 2021$48.66M-85.5%
FY2020Dec 31, 2020$335.66M+1158.2%
FY2019Dec 31, 2019$26.68M-79.3%
FY2018Dec 31, 2018$129.16M–
FY2017Dec 31, 2017$0–
FY2016Dec 31, 2016$0–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$3.60M–
Q2 FY2025Jun 30, 2025$0–
Q4 FY2024Dec 31, 2024$0–
Q3 FY2024Sep 30, 2024$0-100.0%
Q2 FY2024Jun 30, 2024$0-100.0%
Q1 FY2024Mar 31, 2024$0-100.0%
Q4 FY2023Dec 31, 2023$0-100.0%
Q3 FY2023Sep 30, 2023$1.27M-64.4%
Q2 FY2023Jun 30, 2023$294.12M+460.4%
Q1 FY2023Mar 31, 2023$35.14M-16.6%
Q4 FY2022Dec 31, 2022$10.28M-17.8%
Q3 FY2022Sep 30, 2022$3.56M-32.7%
Q2 FY2022Jun 30, 2022$52.48M+128.8%
Q1 FY2022Mar 31, 2022$42.14M+431.9%
Q4 FY2021Dec 31, 2021$12.51M-96.1%
Q3 FY2021Sep 30, 2021$5.29M-43.7%
Q2 FY2021Jun 30, 2021$22.94M+292.3%
Q1 FY2021Mar 31, 2021$7.92M+119.8%
Q4 FY2020Dec 31, 2020$316.82M+6681.1%
Q3 FY2020Sep 30, 2020$9.39M-31.0%
Q2 FY2020Jun 30, 2020$5.85M+39.3%
Q1 FY2020Mar 31, 2020$3.60M-14.3%
Q4 FY2019Dec 31, 2019$4.67M-96.3%
Q3 FY2019Sep 30, 2019$13.60M+1038.4%
Q2 FY2019Jun 30, 2019$4.20M+154.7%
Q1 FY2019Mar 31, 2019$4.21M+556.0%
Q4 FY2018Dec 31, 2018$125.68M–
Q3 FY2018Sep 30, 2018$1.20M–
Q2 FY2018Jun 30, 2018$1.65M–
Q1 FY2018Mar 31, 2018$641.00K–
Q4 FY2017Dec 31, 2017$0–
Q3 FY2017Sep 30, 2017$0–
Q2 FY2017Jun 30, 2017$0–

More Denali Therapeutics figures

See a number that looks wrong?